EP3810201
GIP/GLP1-örva samsetningar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
14.6.2019EP published:
7.6.2023EP application number:
19739766.4
EP translation filed:
19.6.2023Grant published:
15.7.2023EPO information:
European Patent Register
Max expiry date:
13.6.2039Expiry date:
13.6.2026Next due date:
30.6.2026
Title in English:
GIP/GLP1 AGONIST COMPOSITIONSLanguage of the patent:
English
Timeline
Today
14.6.2019EP application
7.6.2023EP Publication
19.6.2023Translation submitted
15.7.2023Registration published
13.6.2026Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
CORVARI, Vincent JohnAddress:
Indianapolis, Indiana 46206-6288, US
Name:
MINIE, Christopher SearsAddress:
Indianapolis, Indiana 46206-6288, US
Name:
MISHRA, Dinesh ShyandeoAddress:
Indianapolis, Indiana 46206-6288, US
Name:
QIAN, Ken KangyiAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862688632 PDate:
22.6.2018Country:
US
Classification
Categories:
A61K 47/02, A61K 47/10, A61K 38/26, A61P 3/10
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 20.7.2023
Expires: 13.6.2024
Payer: Árnason Faktor ehf.
Number: 6
Paid: 21.5.2024
Expires: 13.6.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 4.6.2025
Expires: 13.6.2026
Payer: Árnason Faktor ehf.